Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,573 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Kunisaki C, Takahashi M, Makino H, Oshima T, Fujii S, Takagawa R, Kimura J, Kosaka T, Ono HA, Akiyama H, Kameda K, Kito F, Morita S, Endo I. Kunisaki C, et al. Among authors: morita s. Cancer Chemother Pharmacol. 2011 Jun;67(6):1363-8. doi: 10.1007/s00280-010-1433-7. Epub 2010 Aug 28. Cancer Chemother Pharmacol. 2011. PMID: 20803016 Clinical Trial.
A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial.
Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y, Macdonald JS. Tsuburaya A, et al. Among authors: morita s. Jpn J Clin Oncol. 2005 Nov;35(11):672-5. doi: 10.1093/jjco/hyi179. Epub 2005 Nov 7. Jpn J Clin Oncol. 2005. PMID: 16275676 Clinical Trial.
A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Morita S, Nakata B, Tsuji A, Mitachi Y, Shirasaka T, Saji S, Ohashi Y, Sakamoto J, Hirakawa K. Morita S, et al. Jpn J Clin Oncol. 2007 Dec;37(12):924-9. doi: 10.1093/jjco/hym124. Jpn J Clin Oncol. 2007. PMID: 18211983 Clinical Trial.
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T; Kyushu Taxol TS-1 Study Group. Nakajo A, et al. Among authors: morita s. Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9. doi: 10.1007/s00280-008-0693-y. Epub 2008 Mar 4. Cancer Chemother Pharmacol. 2008. PMID: 18317763 Clinical Trial.
Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.
Ishikawa T, Shimizu S, Katayama K, Chishima T, Hamaguchi Y, Doi T, Tanabe M, Kasahara A, Yamaguchi N, Narui K, Ohta I, Matsumoto C, Shimizu D, Kito A, Suda T, Inaba M, Asaga T, Momiyama N, Ichikawa Y, Yoshimoto M, Morita S, Shimada H. Ishikawa T, et al. Among authors: morita s. Anticancer Res. 2009 May;29(5):1515-20. Anticancer Res. 2009. PMID: 19443359 Free article.
Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, Fujisawa S, Kaneko T, Miyajima E, Morita S, Mori K, Ikeda M, Kato N, Tanaka K. Nozaki A, et al. Among authors: morita s. Arch Virol. 2010 Apr;155(4):601-5. doi: 10.1007/s00705-010-0624-1. Epub 2010 Mar 5. Arch Virol. 2010. PMID: 20204428
3,573 results